Back to Research Home
GILDGilead Sciences Inc
Health Care · Biotechnology · Large
$156.04−0.73%
As of 23 Oct 2026Mkt cap $186B
Stage 13
WAIT
Fundamentals
45.9/75
Technical
5.2/15
Independent
51.1/90
GCAE viewelevated earnings event risk blocks an independent BUY decision
Price
- 1M
- +4.2%
- 3M
- +19.6%
- 6M
- +19.7%
- 1Y
- +28.5%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —Hist median 22.1x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 15.1x
- FCF yield
- 6.6%
Quality
- ROIC
- 22.6%
- Operating margin
- 28.0%
- FCF margin
- 32.1%
- Current ratio
- 1.6x
Growth
- Revenue growth
- +2.4%Latest FY YoY
- Revenue CAGR
- +1.9%
- EPS CAGR
- +8.3%
- FCF CAGR
- −3.3%
Capital
- Share-count trend
- −0.1%3Y annualised
- Net debt
- $18.0B1.8x OCF
Annual trend
- CAGR 2021–2025
- +1.9%
- Latest · 2025
- $29B
- YoY
- +2.4%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
elevated earnings event risk blocks an independent BUY decision
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-29
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded